Project Grant F32AI189066

Award Date 5/18/25
Completion Date Not listed
Dollars Obligated $77K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30329, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,511,827.00 in funding to the Research Institute at Nationwide Children's Hospital to develop an animal model to study the heterogeneous outcomes of Hepatitis C Virus (HCV) infection and pathogenesis. The project aims to identify the viral and immune determinants that lead to spontaneous clearance versus chronic HCV infection using a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Johns Hopkins University aims to compare the immune responses induced by the HEPLISAV-B and ENGERIX-B hepatitis B vaccines in people living with HIV (PLWH). The $1,489,456 award will: Define the innate immune signatures, including plasma chemokine/cytokine and transcriptomic profiles, associated with response to HEPLISAV-B (hepatitis B...
This $2,225,199 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance understanding of the immune responses underlying hepatitis B virus (HBV) functional cure. The primary objectives are to: Define the functions and molecular signatures of HBV-specific CD4 T cells that are important for viral suppression versus functional cure. Characterize HBV-specific humoral...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to advance understanding of virus-host interactions and develop curative therapies for chronic hepatitis B virus (HBV) infections. The research aims to explore the mechanisms by which interferon alpha treatment can lead to HBV cure, investigate the role of HBV genotypes and mutations, and leverage advances in cell culture...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $483,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio. The funding will support a 5-year project to define the protective CD4+ T cell signature that drives effective CD8+ T cell immunity against hepatitis C virus (HCV) infection. The project will leverage historical blood and liver samples from...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $598,764 to The Trustees of Princeton University to conduct research aimed at targeting the hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) to combat chronic HBV infection, particularly in the context of HIV coinfection. The key activities include: Determining whether transient genetic disruption of host factors...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $788,208 to Rockefeller University to develop a mouse model susceptible to chronic hepatitis B virus (HBV) infection. The goal is to identify host and viral determinants that can allow HBV to establish its covalently closed circular DNA (cccDNA) within murine hepatocytes, which is a key barrier to infection in mouse models. The project aims...
This $737,761 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance the efficacy of an HIV vaccine by promoting durable CD4 T follicular helper (Tfh) cell immunity. The primary objective is to induce robust Tfh1 cells, which are essential for generating vigorous B cell activity and persistent antibody responses within germinal centers. The research approach involves...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen (HBsAg) clearance. The $814,790 grant, awarded on November 20, 2024 with a completion date of October 31, 2029, will enable a collaborative effort between researchers at the University of California, San Francisco...

INVESTIGATING THE ROLE OF INTRAHEPATIC PLASMA CELLS IN THE CLEARANCE OF HCV INFECTION: IMPLICATIONS FOR RATIONAL VACCINE DESIGN - PROJECT SUMMARY THE PROPOSED WORK ENTITLED "INVESTIGATING THE ROLE OF INTRAHEPATIC PLASMA CELLS IN THE CLEARANCE OF HCV INFECTION: IMPLICATIONS FOR RATIONAL VACCINE DESIGN" SEEKS TO DETERMINE THE MECHANISTIC ORIGINS OF LIVER-RESIDENT PLASMA CELLS ARISING DURING ACUTE HEPACIVIRAL INFECTION. UNDERSTANDING THESE CUES WOULD IDENTIFY SPECIFIC PREREQUISITES OF INTEREST TO INCORPORATE IN VACCINE REGIMENS AGAINST HEPATITIS C VIRUS (HCV). GIVEN THE ~2 MILLION NEW INFECTIONS OCCURRING ANNUALLY WORLDWIDE, A PROPHYLACTIC HCV VACCINE WOULD THUS PROVIDE SIGNIFICANT PUBLIC HEALTH BENEFIT. WE HAVE RECENTLY DEMONSTRATED THAT AN EARLY GENERATION OF VIRAL-SPECIFIC B CELLS AND ANTIBODIES IS CRITICAL FOR FACILITATING HEPACIVIRAL CLEARANCE IN BOTH HUMANS AND MICE INFECTED WITH HEPATITIS C VIRUS (HCV) AND AN HCV- RELATED RODENT HEPACIVIRUS (RHV), RESPECTIVELY. GIVEN THE ESSENTIAL NATURE OF PRODUCTIVE HUMORAL RESPONSES IN THIS SETTING, IT IS CRITICAL TO UNDERSTAND THE MECHANISTIC PREREQUISITES ENABLING INDIVIDUALS TO MOUNT SUCH A RESPONSE CAPABLE OF DERAILING PERSISTENT INFECTION AS OPPOSED TO SUCCUMBING TO CHRONICITY IN THE ABSENCE OF TIMELY ANTIBODY PRODUCTION. SEEKING TO DETERMINE THE SOURCE OF THIS IMMUNOGLOBULIN PRODUCTION, WE IDENTIFIED A MARKED ANATOMICAL SKEWING OF IGG+ ANTIBODY-SECRETING CELLS (ASCS) WITHIN THE LIVER DURING ACUTE RHV INFECTION, WHILE BEING VIRTUALLY ABSENT IN PERIPHERAL BLOOD, BONE MARROW, SPLEEN, AND LYMPH NODES. DISTINGUISHING WHETHER THIS PHENOMENON REPRESENTED A CONSERVED IMMUNOLOGICAL RESPONSE TO HEPACIVIRAL INFECTION, WE INDEED OBSERVED A ROBUST EXPANSION OF ANTIGEN-SPECIFIC ASCS WITHIN THE LIVER AS OPPOSED TO OTHER TISSUE COMPARTMENTS IN HUMAN HCV INFECTION AS WELL. SERVING TO FURTHER VALIDATE THE UTILITY AND BIOLOGICAL RELEVANCE OF THE RHV INFECTION MODEL FOR INTERROGATING IMMUNOLOGICAL FACETS OF HCV INFECTION, THESE PRELIMINARY FINDINGS NATURALLY ELICIT INVESTIGATION INTO HOW AND WHERE THESE PLASMA CELLS ORIGINATE. OUR IDENTIFICATION OF INTRAHEPATIC GERMINAL CENTER B CELLS AND IGG+ TERTIARY LYMPHOID STRUCTURES (TLSS) ALONGSIDE THE ABSENCE OF APPRECIABLE ASC FORMATION IN SLOS DURING ACUTE RHV INFECTION SUGGESTS THAT THE LIVER MAY BE CAPABLE OF ACTING AS A SURROGATE SECONDARY LYMPHOID ORGAN DURING HEPATOTROPIC INFECTION. FURTHER, AS WE HAVE PREVIOUSLY SHOWN THAT THE WINDOW OF ACUTE INFECTION WHERE B CELLS ARE ESSENTIAL FOR VIRAL RESOLUTION IS WITHIN THE FIRST TWO WEEKS OF INFECTION, THE COINCIDING KINETIC BURST OF PLASMA CELLS ARISING WITHIN THE LIVER AROUND THIS TIME FRAME SUGGESTS THAT THIS INTRAHEPATIC HUMORAL RESPONSE IS INTEGRAL FOR FACILITATING ULTIMATE VIRAL ELIMINATION. GIVEN THE CRITICAL NATURE OF THIS RESPONSE, THE PROPOSED STUDIES AIM TO CHARACTERIZE THE MECHANISTIC UNDERPINNINGS OF HOW AND WHERE PLASMA CELL RESPONSES ARE GENERATED DURING HEPATOTROPIC INFECTION. EITHER OUTCOME, DETERMINING WHETHER THEY FOLLOW TRADITIONAL SLO PRIMING AND INFLAMMATORY HOMING PATTERNS OR ARE PRIMED LOCALLY WITHIN THE LIVER PARENCHYMA, SHOULD PROVIDE VALUABLE INSIGHTS THAT ARE HIGHLY RELEVANT TO BASIC IMMUNOLOGICAL PARADIGMS. FURTHERMORE, THE PROPOSED WORK SHOULD INFORM STRATEGIES TO ENABLE FUNCTIONAL RECAPITULATION OF THESE PRODUCTIVE, ESSENTIAL RESPONSES IN THE RATIONAL DESIGN OF AN EFFICACIOUS VACCINE AGAINST HCV.

Posted 11/18/24, 12:00 AM